Related Experiment Videos
Prostacyclin in cardiopulmonary bypass operations
The Journal of Thoracic and Cardiovascular Surgery
|October 1, 1982
Summary
Prostacyclin (PGI2) did not significantly reduce postoperative blood loss in cardiac surgery patients. However, PGI2 may decrease platelet and fibrin deposition on bypass filters, potentially reducing visceral injury.
Area of Science:
- Cardiovascular Surgery
- Pharmacology
- Biomedical Engineering
Background:
- Cardiopulmonary bypass circuits can accumulate deposits on filters.
- Prostacyclin (PGI2) is a vasodilator and inhibitor of platelet aggregation.
- The impact of PGI2 on filter deposition and bleeding during cardiac surgery requires investigation.
Purpose of the Study:
- To evaluate the effect of prostacyclin (PGI2) on postoperative blood loss.
- To assess PGI2's influence on deposits forming on arterial line filters during cardiopulmonary bypass.
- To explore PGI2's potential role in mitigating visceral injury in cardiac operations.
Main Methods:
- A double-blind, randomized study involving 56 patients undergoing elective cardiac operations.
- Administration of either PGI2 or a placebo solution during cardiopulmonary bypass.
- Measurement of postoperative blood loss and analysis of arterial line filter weight and electron microscopic appearance.
Main Results:
- No statistically significant difference in postoperative blood loss between PGI2 and placebo groups.
- Changes in filter weight and microscopic appearance suggest PGI2 reduces platelet and fibrin deposition.
- PGI2 demonstrated a potential to decrease filter mesh deposition.
Conclusions:
- Prostacyclin (PGI2) does not significantly alter postoperative bleeding in patients undergoing cardiopulmonary bypass.
- PGI2 may reduce the deposition of platelets and fibrin on arterial line filters.
- PGI2 could be beneficial in reducing visceral injury during cardiac operations by minimizing filter deposition.